The Effects of Momordica charantia on Type 2 Diabetes Mellitus and Alzheimer’s Disease
Authors
Erika Richter
Department of Nutritional Sciences, Auburn University, Auburn, AL 36849, USA
Thangiah Geetha
Department of Nutritional Sciences, Auburn University, Auburn, AL 36849, USA
Donna Burnett
Department of Nutritional Sciences, Auburn University, Auburn, AL 36849, USA
Tom Broderick
Department of Physiology, Laboratory of Diabetes and Exercise Metabolism, College of Graduate Studies, Midwestern University, Glendale, AZ 85308, USA
Jeganathan Babu
Department of Nutritional Sciences, Auburn University, Auburn, AL 36849, USA
T2DM is a complex metabolic disorder characterized by hyperglycemia and glucose intolerance. It is recognized as one of the most common metabolic disorders and its prevalence continues to raise major concerns in healthcare globally. Alzheimer’s disease (AD) is a gradual neurodegenerative brain disorder characterized by the chronic loss of cognitive and behavioral function. Recent research suggests a link between the two diseases. Considering the shared characteristics of both diseases, common therapeutic and preventive agents are effective. Certain bioactive compounds such as polyphenols, vitamins, and minerals found in vegetables and fruits can have antioxidant and anti-inflammatory effects that allow for preventative or potential treatment options for T2DM and AD. Recently, it has been estimated that up to one-third of patients with diabetes use some form of complementary and alternative medicine. Increasing evidence from cell or animal models suggests that bioactive compounds may have a direct effect on reducing hyperglycemia, amplifying insulin secretion, and blocking the formation of amyloid plaques. One plant that has received substantial recognition for its numerous bioactive properties is Momordica charantia (M. charantia), otherwise known as bitter melon, bitter gourd, karela, and balsam pear. M. charantia is utilized for its glucose-lowering effects and is often used as a treatment for diabetes and related metabolic conditions amongst the indigenous populations of Asia, South America, India, and East Africa. Several pre-clinical studies have documented the beneficial effects of M. charantia through various postulated mechanisms. Throughout this review, the underlying molecular mechanisms of the bioactive components of M. charantia will be highlighted. More studies will be necessary to establish the clinical efficacy of the bioactive compounds within M. charantia to effectively determine its pertinence in the treatment of metabolic disorders and neurodegenerative diseases, such as T2DM and AD.
Keywords: bitter melon (M. charantia), type 2 diabetes mellitus, Alzheimer’s disease, glucose-lowering effects, hypoglycemic, medicinal plants, natural, neuroprotective, prevalence, therapeutic, bioactive
Author Biographies
Thangiah Geetha, Department of Nutritional Sciences, Auburn University, Auburn, AL 36849, USA
Boshell Metabolic Diseases and Diabetes Program, Auburn University, Auburn, AL 36849, USA
Donna Burnett, Department of Nutritional Sciences, Auburn University, Auburn, AL 36849, USA
Boshell Metabolic Diseases and Diabetes Program, Auburn University, Auburn, AL 36849, USA
Jeganathan Babu, Department of Nutritional Sciences, Auburn University, Auburn, AL 36849, USA
Boshell Metabolic Diseases and Diabetes Program, Auburn University, Auburn, AL 36849, USA
Click on "Archives" to access the full archive of scientific preprints. You may use the categories and the search functionality to find select preprints you're interested in.
